PDF herunterladen
Synlett 2015; 26(04): 489-493
DOI: 10.1055/s-0034-1379549
letter
© Georg Thieme Verlag Stuttgart · New York

Synthesis of a ‘Propeller-Like’ Oligoheteroaryl with Alternating Pyridine and Oxazole Motifs

Savvas N. Georgiades*
Department of Chemistry, University of Cyprus, 1 Panepistimiou Ave., Aglandjia, Nicosia 2109, Cyprus   Fax: +357(22)895456   eMail: georgiades.savvas@ucy.ac.cy
,
Natalia Rizeq
Department of Chemistry, University of Cyprus, 1 Panepistimiou Ave., Aglandjia, Nicosia 2109, Cyprus   Fax: +357(22)895456   eMail: georgiades.savvas@ucy.ac.cy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 14. Oktober 2014

Accepted after revision: 24. Oktober 2014

Publikationsdatum:
08. Januar 2015 (online)

    Lizenzen und Reprints Alle Artikel dieser Rubrik


Abstract

The molecular architecture of oligomeric pyridyl-oxazole compounds is key to determining their mode of interaction with G-quadruplex DNA structures, which is a family of prominent anticancer biomolecular targets. We report herein an efficient synthetic route that begins with chelidamic acid and affords, in just seven steps, an unusual ‘propeller-like’ pyridyl-oxazole architecture with alternating pyridine and oxazole rings, that has not been yet validated as a G-quadruplex binder. The synthesis employs Van Leusen chemistry for the construction of oxazole rings from aldehydes, and two Pd(II)/Cu(I)-mediated cross-coupling reactions involving C–H activation of oxazoles for the formation of C–C bonds between bromopyridine intermediates and oxazole fragments. This modular synthesis was designed to be amenable to the construction of analogues.

Key words

anticancer - oligoheteroaryl - propeller architecture - C-H activation - G-quadruplex

Supporting Information

    Supporting information for this article is available online at http://dx.doi.org/10.1055/s-0034-1379549.
  • Supporting Information
 

  • References and Notes

  • 1 Shin-ya K, Wierzba K, Matsuo K.-L, Ohtani T, Yamada Y, Furihata K, Hayakawa Y, Seto H. J. Am. Chem. Soc. 2001; 123: 1262
    Crossref
  • 2 Kim M.-Y, Vankayalapati H, Shin-ya K, Wierzba K, Hurley LH. J. Am. Chem. Soc. 2002; 124: 2098
    Crossref
    • 3a Yamada S, Shigeno K, Kitagawa K, Okajima S, Asao T (Taiho Pharmaceutical Co. Ltd., Sosei Co. Ltd.) 200248153, 2002 ; Chem. Abstr. 2002, 137, 47050
    • 3b Endoh N, Tsuboi K, Kim R, Yonezawa Y, Shin C. Heterocycles 2003; 60: 1567
      Crossref
    • 3c Deeley J, Pattenden G. Chem. Commun. 2005; 797
    • 3d Doi T, Yoshida M, Shin-ya K, Takahashi T. Org. Lett. 2006; 8: 4165
      CrossrefPubMed
    • 3e Minhas GS, Pilch DS, Kerrigan JE, LaVoie EJ, Rice JE. Bioorg. Med. Chem. Lett. 2006; 16: 3891
      Crossref
    • 3f Tera M, Ishizuka H, Takagi M, Suganuma M, Shin-ya K, Nagasawa K. Angew. Chem. Int. Ed. 2008; 47: 5557
      Crossref
    • 3g Rzuczek SG, Pilch DS, LaVoie EJ, Rice JE. Bioorg. Med. Chem. Lett. 2008; 18: 913
      Crossref
  • 4 Rzuczek SG, Pilch DS, Liu A, Liu L, LaVoie EJ, Rice JE. J. Med. Chem. 2010; 53: 3632
    Crossref
    • 5a Huppert JL, Balasubramanian S. Nucleic Acids Res. 2005; 33: 2908
      Crossref
    • 5b Todd AK. Methods 2007; 43: 246
      Crossref
    • 5c Todd AK, Haider SM, Parkinson GN, Neidle S. Nucleic Acids Res. 2007; 35: 5799
      Crossref
    • 5d Huppert JL, Balasubramanian S. Nucleic Acids Res. 2007; 35: 406
  • 6 Du Z, Zhao Y, Li N. Genome Res. 2008; 18: 233
    Crossref
  • 7 Hamon F, Largy E, Guédin-Beaurepaire A, Rouchon-Dagois M, Sidibe A, Monchaud D, Mergny J.-L, Riou J.-F, Nguyen C.-H, Teulade-Fichou M.-P. Angew. Chem. Int. Ed. 2011; 50: 8745
    Crossref
  • 8 Petenzi M, Verga D, Largy E, Hamon F, Doria F, Teulade-Fichou M.-P, Guédin A, Mergny J.-L, Mella M, Freccero M. Chem. Eur. J. 2012; 18: 14487
    Crossref
  • 9 Data for compound 2: 1H NMR (CDCl3): δ = 1.41 (t, J = 7.1 Hz, 6 H), 4.46 (q, J = 7.1 Hz, 4 H), 7.35 (s, 2 H). 13C NMR (CDCl3 + trace DMSO-d 6): δ = 13.6, 61.6, 115.6, 148.1, 163.9, 167.1. MS (ESI): m/z = 238.08 (calcd 238.07 [M – H]–), 261.06 (calcd 261.06, [M + Na – H]–).
  • 10 Cooper CG. F, MacDonald JC, Soto E, McGimpsey WE. J. Am. Chem. Soc. 2004; 126: 1032
    Crossref
  • 11 Data for compound 3: 1H NMR (CDCl3): δ = 1.45 (t, J = 7.2 Hz, 6 H), 4.49 (q, J = 7.2 Hz, 4 H), 8.42 (s, 2 H). 13C NMR (CDCl3): δ = 14.1, 62.7, 131.0, 134.9, 149.5, 163.5. MS (ESI): m/z = 302.01 (calcd 302.00, [M + H]+).
  • 12 Data for compound 4: 1H NMR (CDCl3): δ = 7.13 (t, J =7.0 Hz, 1 H), 7.55 (d, J = 7.0 Hz, 1 H), 7.61 (s, 1 H), 7.65 (t, J = 7.0 Hz, 1 H), 7.89 (s, 1 H), 8.53 (d, J = 7.0 Hz, 1 H). 13C NMR (CDCl3): δ = 119.0, 122.7, 124.5, 136.6, 146.7, 149.5, 150.7, 150.8. MS (ESI): m/z = 147.06 (calcd 147.06, [M + H]+).
  • 13 Data for compound 5: 1H NMR (CDCl3): δ = 1.46 (t, J = 7.2 Hz, 6 H), 4.51 (q, J = 7.2 Hz, 4 H), 7.29 (td, J 1 = 5.5 Hz, J 2=2.8 Hz, 1 H), 7.80–7.82 (m, 2 H, overlapping), 7.90 (s, 1 H), 8.65 (dt, J 1 = 4.7 Hz, J 2 = 1.5 Hz, 1 H), 8.87 (s, 2 H). 13C NMR (CDCl3): δ = 14.1, 62.5, 119.7, 123.6, 123.8, 127.6, 136.5, 137.0, 146.2, 149.6, 150.0, 152.5, 158.0, 164.0. MS (ESI): m/z = 368.12 (calcd 368.13, [M + H]+).
    • 14a Zificsak CA, Hlasta DJ. Tetrahedron 2004; 60: 8991
      Crossref
    • 14b Besselièvre F, Mahuteau-Betzer F, Grierson DS, Piguel S. J. Org. Chem. 2008; 73: 3278
      Crossref
    • 14c Besselièvre F, Lebrequier S, Mahuteau-Betzer F, Piguel S. Synthesis 2009; 3511
      Artikel in Thieme Connect
    • 15a Seregin IV, Schammel AW, Gevorgyan V. Org. Lett. 2007; 9: 3433
      Crossref
    • 15b Seregin IV, Schammel AW, Gevorgyan V. Tetrahedron 2008; 64: 6876
      CrossrefPubMed
  • 16 Data for compound 6: 1H NMR (DMSO-d 6): δ = 4.63 (d, J = 6.1 Hz, 4 H), 5.63 (t, J = 6.1 Hz, 2 H), 7.44 (t, J = 5.8 Hz, 1 H), 7.96–7.98 (m, 4 H, overlapping), 8.06 (s, 1 H), 8.69 (d, J = 5.0 Hz, 1 H). 13C NMR (DMSO-d 6): δ = 64.1, 114.2, 119.9, 123.9, 127.4, 134.4, 137.6, 146.1, 150.1, 151.5, 159.7, 162.8. MS (ESI): m/z = 282.10 (calcd 282.09, [M – H]–).
  • 17 Data for compound 7: 1H NMR (CDCl3): δ = 7.30 (t, J = 5.6 Hz, 1 H), 7.80–7.84 (m, 2 H, overlapping), 7.91 (s, 1 H), 8.66 (d, J = 4.7 Hz, 1 H), 8.76 (s, 2 H), 10.20 (s, 2 H). 13C NMR (CDCl3): δ = 120.3, 121.5, 124.1, 128.4, 136.7, 138.0, 145.6, 149.7, 152.0, 153.9, 158.1, 191.6. MS (ESI): m/z = 280.06 (calcd 280.07, [M + H]+).
  • 18 Georgiades SN, Clardy J. Bioorg. Med. Chem. Lett. 2008; 18: 3117
    Crossref
  • 19 Frigerio M, Santagostino M, Sputore S. J. Org. Chem. 1999; 64: 4537
    Crossref
  • 20 Leusen DV, Leusen AM. V. Synthetic Uses of Tosylmethyl Isocyanide (TosMIC) . In Organic Reactions . Vol. 57. Wiley-VCH; Weinheim: 2004: 417
    Google Scholar
  • 21 Data for compound 8: 1H NMR (CDCl3): δ = 7.31 (t, J = 5.6 Hz, 1 H), 7.83–7.87 (m, 4 H, overlapping), 7.93 (s, 1 H), 8.05 (s, 2 H), 8.26 (s, 2 H), 8.69 (d, J = 4.5 Hz, 1 H). 13C NMR (CDCl3 + trace CD3OD): δ = 114.0, 114.8, 119.9, 123.6, 126.3, 127.5, 131.4, 136.1, 137.2, 146.5, 148.3, 150.1, 152.2, 158.9. MS (ESI): m/z = 358.10 (calcd 358.10, [M + H]+).
  • 22 Data for compound 10: 1H NMR (CDCl3): δ = 7.33 (dd, J 1 =7.9, J 2 = 4.9 Hz, 1 H), 7.45 (dd, J 1 = 7.9, J 2 = 4.9 Hz, 2 H), 7.85–7.95 (m, 3 H, overlaid), 7.95 (d, J = 6.5 Hz, 1 H), 7.96 (s, 1 H), 8.08 (s, 2 H), 8.30 (d, J = 7.9 Hz, 2 H), 8.49 (s, 2 H), 8.72 (d, J = 4.9 Hz, 1 H), 8.83 (d, J = 4.1 Hz, 2 H). 13C NMR (CDCl3): δ = 115.1, 120.0, 122.7, 123.6, 125.1, 127.6, 128.8, 136.2, 137.0, 137.2, 145.8, 146.7, 148.3, 149.0, 150.2, 151.2, 152.5, 159.1, 161.2. MS (ESI): m/z = 512.14 (calcd 512.15, [M + H]+).